Jane Street Group, LLC Molecular Partners Ag Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.8 - $7.32 $910 - $1,149	-157 Reduced 0.92%	16,816 $101,000
Q4 2022 Feb 14, 2023	SELL	$6.03 - $7.08 $40,672 - $47,754	-6,745 Reduced 28.44%	16,973 $111,000
Q3 2022 Nov 14, 2022	SELL	$5.6 - $7.09 $18,625 - $23,581	-3,326 Reduced 12.3%	23,718 $159,000
Q3 2022 Nov 14, 2022	SELL	$5.6 - $7.09 $18,625 - $23,581	-3,326 Reduced 12.3%	23,718 $159,000
Q2 2022 Aug 16, 2022	SELL	$5.98 - $21.8 $12,641 - $46,085	-2,114 Reduced 7.25%	27,044 $183,000
Q1 2022 May 17, 2022	SELL	$16.51 - $31.89 $29,916 - $57,784	-1,812 Reduced 5.85%	29,158 $591,000
Q4 2021 Feb 15, 2022	BUY	$9.99 - $20.49 $309,390 - $634,575	30,970 New	30,970 $594,000

849K

Ticker MOLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,514,000
Market Cap $169M
Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.